Follows adults with psoriasis treated with approved therapies to study safety
Tracks safety of psoriasis treatments, including newer biologic drugs, in adults.
Plain-language title generated from the registry record
Registry title: The CorEvitas Psoriasis (PSO) Registry
Key facts
- Where
- Waltham, United StatesSee the site
Where in United States
- WalthamWaltham, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- CorEvitas
- Trial code
- NCT02707341
- Record updated
- 27 August 2026
- Original description
The primary objective of the CorEvitas Psoriasis Registry is to study the comparative safety of approved psoriasis therapies in a North American cohort of psoriasis subjects treated by dermatologists. This includes assessing the incidence and nature of adverse events of special interest, including malignancy, in a real world population of psoriasis patients on new biologic therapies (e.g. secukinumab). Secondary objectives include analyzing the epidemiology and natural history of the disease, comorbidities, current treatment practices, and comparative effectiveness.Read full original descriptionShow less
CorEvitas Psoriasis (PSO) Registry
The primary objective of the CorEvitas Psoriasis Registry is to study the comparative safety of approved psoriasis therapies in a North American cohort of psoriasis subjects treated by dermatologists. This includes assessing the incidence and nature of adverse events of special interest, including malignancy, in a real world population of psoriasis patients on new biologic therapies (e.g. secukinumab). Secondary objectives include analyzing the epidemiology and natural history of the disease, comorbidities, current treatment practices, and comparative effectiveness.
Inclusion: The patient must:; Have been diagnosed with psoriasis by a dermatologist; Be at least 18 years of age or older; Be willing and able to provide written consent for participation in the registry; Be willing and able to provide Personally Identifiable Information (PII) that includes the following types of personal information at a minimum: 1) Full Name and 2) Date of Birth; Meet one of the following criteria; Have started on or switched to a systemic psoriasis treatment within the previous 12 months†▲:.
Exclusion: Patient is participating in or planning to participate in a double-blind randomized of a psoriasis drug. Of note, concurrent participation in another observational registry or open-label Phase 3b/4 trial is not excluded.
ELIGIBILITY CRITERIA∗ To be eligible for enrollment into the CorEvitas Psoriasis Registry, a patient must satisfy all of the inclusion criteria and none of the exclusion criteria listed below.